Home » Topics » BioWorld Science

BioWorld Science
RSS

Jiangsu Hengrui Medicine patents PTPN11 inhibitors

July 20, 2022

Novel CDK9 inhibitor with good antiproliferative activity in hematologic cancer models

July 20, 2022

AZD-1390 induces dramatic recovery after spinal cord injury in preclinical models

July 20, 2022

Hepsin contributes to metastasis and thrombosis in patients with CRC, study finds

July 20, 2022

Novel HDAC3 inhibitor shows antitumor activity in 4T1-Luc xenograft mouse model

July 19, 2022

Researchers unveil novel markers involved in pulmonary embolism

July 19, 2022

Organoid efficacy data leads to approval of clinical trial of rare disease drug

July 19, 2022

Targeting GABA-transported GAT-3 in astrocytes reduces negative outcomes of brain injury

July 19, 2022

Chinese researchers synthesize new vasopressin receptor antagonists

July 19, 2022

Jiangsu Tasly Diyi Pharmaceutical presents new FXR agonists

July 19, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...